← ANALYST RATINGS · TIPRANKS
Capricor Therapeutics (CAPR): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy6 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $27.00, the highest $54.00, the lowest $7.00. The average is +302.4% from the last price of $6.71.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $7.50+15.4% | Hold | +11.8% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.50 → $7.00+7.7% | Hold | +4.3% | Upgrade | 16.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $7.00+7.7% | Hold | +4.3% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 → $7.00+16.7% | Sell | +4.3% | Downgrade | 16.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.50 → $7.00+7.7% | Hold | +4.3% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $7.00+7.7% | Hold | +4.3% | Reiterated | 16.10.26on TipRanks 18:05 | — | |
| Boobalan Pachaiyappan★★★★★★★★★★#11894 · hits 38% · avg −7.5% | Roth MKM | $7.00 | Hold | +4.3% | Reiterated | 05.10.26on TipRanks 10:30 | −13.7%next day −0.9% · 5 days −4.4% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | — | Hold | — | Reiterated | 05.10.26on TipRanks 10:11 | −13.7%next day −0.9% · 5 days −4.4% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | — | Hold | — | Reiterated | 27.09.26on TipRanks Sep 28 01:05 | +4.9%next day −1.4% · 5 days −11.9% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $5.00 → $21.00+320.0% | Buy | +213.0% | Upgrade | 14.09.26on TipRanks 07:25 | +5.7%next day −2.4% · 5 days −0.9% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $2.00 → $25.00+1,150.0% | Buy | +272.6% | Upgrade | 01.09.26on TipRanks 04:30 | +1.7%next day −1.6% · 5 days −13.8% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $54.00 | Buy | +704.8% | Upgrade | 25.08.26on TipRanks Aug 26 04:55 | +21.6%next day +12.9% · 5 days +21.3% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | — | Hold | — | Reiterated | 14.08.26on TipRanks Aug 15 14:10 | +58.2%next day +12.5% · 5 days −4.0% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $3.50 → $28.00+700.0% | Buy | +317.3% | Upgrade | 14.08.26on TipRanks 05:10 | +58.2%next day +12.5% · 5 days −4.0% | ↗ |
| Rick Bienkowski★★★★★★★★★★#12090 · hits 19% · avg −23.3% | Ladenburg Thalmann & Co. | — | Hold | — | Downgrade | 30.07.26on TipRanks 07:35 | −37.9%next day −8.8% · 5 days −3.9% | ↗ |
| Matthew Venezia★★★★★★★★★★#10510 · hits 33% · avg −7.8% | Alliance Global Partners | — | Hold | — | Reiterated | 30.07.26on TipRanks Jul 28 07:10 | −6.3%next day +1.5% · 5 days −40.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Capricor Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $27.00 at a price of $9.47 (+185.1%); now: $27.00 at $6.71 (+302.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 12 | 15 | 7 | 7 | 4 |
| Buy | 8 | 4 | 4 | 1 | 1 | 0 |
| Hold | 0 | 0 | 10 | 17 | 18 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.74 to $2.27). Last quarter: $-0.70.
Sales
Next quarter’s sales estimate — $42M (from $0M to $200M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Capricor Therapeutics
- CEO: Linda Marbán
- Employees: 231
- 10865 Road to the Cure, San Diego, CA, 92121, US
- www.capricor.com
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Data from the stock’s TipRanks forecast page, read 28 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗